{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:43:58Z","timestamp":1773780238794,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.clml.2018.02.004","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T22:48:34Z","timestamp":1518043714000},"page":"266-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial"],"prefix":"10.1016","volume":"18","author":[{"given":"S\u00e9bastien","family":"Rinaldetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Pfirrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7740-4076","authenticated-orcid":false,"given":"Kirsi","family":"Manz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joelle","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panayiotidis","family":"Panagiotidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Seifarth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Fabarius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Pagoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Dimou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Dengler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelius F.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Burchert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Jan\u03b2en","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elisabeth","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp J.","family":"Jost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Hanzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Schafhausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Prange-Krex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Illmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Janzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Klausmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"B\u00fcschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.02.004_bib1","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Sau\u03b2ele","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.004_bib2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.02.004_bib3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.V128.22.787.787","article-title":"Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski trial","volume":"128","author":"Mahon","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.004_bib4","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.004_bib5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V128.22.789.789","article-title":"No differences in molecular relapse-free survival after stopping imatinib treatment of chronic myeloid leukemia between patients with prior 4.5 log reduction (MR4.5) but detectable and patients with undetectable disease in the EURO-SKI Trial","volume":"128","author":"Pfirrmann","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.004_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/leu.2017.9","article-title":"Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML","volume":"31","author":"Sch\u00fctz","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.004_bib7","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.004_bib8","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.004_bib9","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.02.004_bib10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","article-title":"Drug transporters and imatinib treatment: implications for clinical practice","volume":"17","author":"Eechoute","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.02.004_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.bjp.0704785","article-title":"Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3","volume":"136","author":"Hayer-Zillgen","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clml.2018.02.004_bib12","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","article-title":"In\u00a0vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML","volume":"106","author":"White","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.004_bib13","first-page":"507","article-title":"The functional activity of the OCT-1 protein is predictive of molecular response and survival in CP-CML patients treated with imatinib: a 5 year update of the TIDEL trial","volume":"114","author":"White","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2018.02.004_bib14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT 1 and resistance to imatinib","volume":"106","author":"Crossman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.004_bib15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clml.2018.02.004_bib16","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.004_bib17","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.004_bib18","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.004_bib19","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1124\/mol.65.6.1485","article-title":"High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter","volume":"65","author":"Ozvegy-Laczka","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.clml.2018.02.004_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcp.2009.04.002","article-title":"Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1\/Pgp and ABCG2\/BCRP\/MXR transporters","volume":"78","author":"Tiwari","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clml.2018.02.004_bib21","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","article-title":"Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties","volume":"158","author":"Hegedus","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clml.2018.02.004_bib22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":"Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib","volume":"38","author":"Dohse","year":"2010","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"10.1016\/j.clml.2018.02.004_bib23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/clpt.2013.208","article-title":"Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib","volume":"95","author":"Eadie","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clml.2018.02.004_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2016.179","article-title":"The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment","volume":"31","author":"Eadie","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.004_bib25","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/leu.2014.6","article-title":"MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure","volume":"28","author":"Agrawal","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.004_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs-2016-0103","article-title":"Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis","volume":"18","author":"Jiang","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clml.2018.02.004_bib27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/sj.leu.2404983","article-title":"Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories","volume":"22","author":"M\u00fcller","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.004_bib28","series-title":"Bootstrap Methods and Their Application","author":"Davison","year":"1997"},{"key":"10.1016\/j.clml.2018.02.004_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jnci\/86.11.829","article-title":"Dangers of using \u201coptimal\u201d cut points in the evaluation of prognostic factors","volume":"86","author":"Altman","year":"1994","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2018.02.004_bib30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1198\/106186006X133933","article-title":"Unbiased recursive partitioning: a conditional inference framework","volume":"15","author":"Hothorn","year":"2006","journal-title":"J\u00a0Comput Graph Stat"},{"key":"10.1016\/j.clml.2018.02.004_bib31","doi-asserted-by":"crossref","first-page":"e88298","DOI":"10.1371\/journal.pone.0088298","article-title":"PTEN regulates BCRP\/ABCG2 and the side population through the PI3K\/Akt pathway in chronic myeloid leukemia","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2018.02.004_bib32","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3109\/10428194.2011.584005","article-title":"Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1","volume":"52","author":"Gromicho","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.02.004_bib33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4161\/cbt.7.3.5412","article-title":"Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib","volume":"7","author":"Gardner","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clml.2018.02.004_bib34","doi-asserted-by":"crossref","first-page":"41918","DOI":"10.1074\/jbc.M405652200","article-title":"The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells","volume":"279","author":"Ertmer","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2018.02.004_bib35","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1111\/j.1742-4658.2009.07423.x","article-title":"Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2","volume":"276","author":"Nakagawa","year":"2009","journal-title":"FEBS J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017319122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017319122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:52Z","timestamp":1761870592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017319122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S2152265017319122"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.02.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}